N,N-Dimethylformamide (DMF), CAS 68-12-2, is supplied as product code DMF-VET-01 for tablet, capsule, powder, granule, premix, and oral solution manufacturing, and as DMF-VET-02 for injectable systems requiring reduced water and endotoxin burden. The molecular formula is C3H7NO and molar mass is 73.09 g/mol. Density at 20 °C is 0.944 g/cm³; dynamic viscosity at 25 °C is approximately 0.80 mPa·s. The boiling point at 101.3 kPa is 153 °C, freezing point is -61 °C, and refractive index at 20 °C is approximately 1.430. The product is a clear, anhydrous, dipolar aprotic liquid fully miscible with water, methanol, ethanol, isopropanol, acetone, ethyl acetate, and chloroform. The commercial designation “API” denotes a pharmaceutical processing grade solvent and processing aid rather than an active pharmacophore. Principal functions include granulation solvent in tablet and capsule lines, dissolution medium for poorly water-soluble veterinary actives, spray carrier in powder and premix adsorption, and co-solvent in aqueous or non-aqueous oral solutions.

Two grades are released against separate specification limits. DMF-VET-01 is specified for solid oral and premix manufacturing. DMF-VET-02 is specified for injectable formulation development where reduced water and endotoxin levels are required. Both grades share compendial identity and assay profiles; the injectable grade undergoes additional bacterial endotoxin and particulate control testing using USP <85> or Ph. Eur. 2.6.14 as appropriate. Release data for distilled material typically show assay values between 99.8% and 99.9% area percent, with water content varying by less than 0.02% w/w in unopened containers.

What Limits the Residual Solvent Load in Veterinary Dosage Forms?

DMF is listed in ICH Q3C(R8) Table 2 and VICH GL18(R2) as a Class 2 residual solvent with a permitted daily exposure of 8.8 mg/day and an Option 2 concentration limit of 880 ppm. In tablet and capsule manufacture, residual DMF is therefore a release-limiting quality attribute when the drug substance synthesis or granulation route introduces DMF. Finished product analysis is normally performed by headspace gas chromatography with flame ionization detection, following USP <467> Procedure A or equivalent. Quantitation at or below 10 ppm is required for products with low daily dose mass because Option 1 scaling may reduce the allowable concentration below the Option 2 value.

In tablet and capsule manufacturing, DMF is introduced during high-shear granulation as a binder solvent or as a solvent for a poorly soluble veterinary active. A typical process uses a bottom-drive high-shear granulator with a chopper speed of 1,500–3,000 rpm and binder addition through a peristaltic spray nozzle at a rate of 0.5–2.0 kg/min. After wet massing, the granulate is discharged to a fluid-bed dryer. The drying step creates the primary process conflict: the DMF boiling point of 153 °C prevents rapid removal at low inlet air temperatures, but inlet air temperatures above 75 °C can cause surface hardening of povidone-bound granules and reduce tablet hardness. A validated drying range of 70 °C ± 5 °C, with endpoint moisture below 2.0% w/w by loss on drying, typically reduces residual DMF below 500 ppm in placebo granulations. Drug-containing granulations require case-by-case confirmation because API-solvent binding can slow desorption. Published data for this specific veterinary configuration are limited; development batches should include a placebo control to separate solvent retention caused by the matrix from retention caused by the active phase.

When DMF Is Pumped into Injectable Aqueous Systems

DMF-VET-02 is used as a water-miscible co-solvent for poorly water-soluble actives in injectable formulations, typically at 5–30% v/v after biocompatibility assessment. Bulk solvent is not supplied as sterile; it is introduced into the formulation upstream of a sterilizing-grade filtration step. Polyvinylidene fluoride or polytetrafluoroethylene membranes rated at 0.22 µm are preferred because DMF can swell cellulose ester and polyethersulfone membranes. The solvent contribution to the finished product endotoxin load is controlled by purchasing DMF-VET-02 at ≤0.25 EU/mL and by depyrogenating the filtration train at 250 °C for not less than 30 minutes where dry heat is used.

Hydrolytic stability is the main injectable formulation constraint. DMF is susceptible to acid- and base-catalyzed hydrolysis, generating formic acid and dimethylamine. Aqueous solutions containing DMF should be buffered to pH 5.0–7.0 and held at 15–25 °C during compounding and filling. Holding times at pH above 8.0 or temperatures above 40 °C should be justified by pH drift and dimethylamine assay. Unbuffered DMF-water systems stored in Type I borosilicate glass vials may show increased acidity after terminal moist-heat cycles, so terminal sterilization conditions require validation against hydrolysis products. For food-producing species, residual solvent exposure must be considered within the total toxicological load and residue-depletion assessment; published data for specific DMF residues in edible tissues are limited.

In powder and premix manufacture, DMF is sprayed as a binder or active-carrier solution onto a lactose, starch, or cellulose carrier in a ribbon blender fitted with a heated jacket at 40–50 °C. The vapor pressure of DMF at 20 °C is approximately 0.36 kPa, so residual solvent removal cannot be achieved by simple air purge alone. After spraying, the premix is transferred to a vacuum tray dryer at 50–60 °C and 10–50 kPa absolute until headspace-GC analysis shows DMF below the 880 ppm VICH GL18(R2) Option 2 limit. Blender jacket temperatures above 55 °C are avoided for free-flowing premixes because surface moisture migration can cause clumping and non-uniform active distribution.

Solvation, Boiling Range, and Moisture Uptake Relative to Dimethyl Sulfoxide, N-Methyl-2-Pyrrolidone, and Dimethylacetamide

The choice of DMF over other dipolar aprotic solvents is governed by four measurable properties: boiling point, dielectric constant, residual solvent class, and hydrolytic tendency. DMF has a lower boiling point (153 °C) than dimethyl sulfoxide (189 °C), dimethylacetamide (165 °C), and N-methyl-2-pyrrolidone (202 °C); this favors removal by vacuum drying in tablet and granule lines. Dielectric constant at 25 °C is 36.7, compared with 46.7 for DMSO, 37.8 for DMAc, and 32.2 for NMP. For high-polarity veterinary actives requiring a strong hydrogen-bond acceptor solvent, DMSO provides stronger polarity but is more difficult to remove, while DMF offers a lower boiling range and better compatibility with several tablet binder systems.

For residual solvent control, DMAc may offer a slightly higher permitted daily exposure (10.9 mg/day) than DMF, but its boiling point is 12 °C higher, requiring longer drying cycles. NMP is the tightest residual solvent in this group (5.3 mg/day), which reduces formulation flexibility. DMSO is Class 3 with no PDE assigned, but its high boiling point (189 °C) and low vapor pressure often make removal from granules impractical without high vacuum. DMF therefore occupies an intermediate position: its PDE of 8.8 mg/day is less restrictive than NMP but more restrictive than DMAc, while its boiling point is lower than both, favoring drying.

Release, Retest Period, and Container-Lining Compatibility Data Are Generated Under Nitrogen Blanketing

DMF-VET-01 and DMF-VET-02 are filled under a nitrogen overlay of 0.3–0.5 bar into epoxy-phenolic lined steel drums or high-density polyethylene drums. Retest period is 24 months from manufacture when stored in unopened containers at 15–25 °C and protected from moisture. Opened containers exposed to ambient relative humidity above 60% should be retested for water content before use because DMF is hygroscopic and water uptake can reach 0.005–0.01% w/w per day depending on headspace volume and ambient humidity. Nitrogen blanketing is recommended after each partial discharge; for drums fitted with drum pumps, a silica-gel breather vent is not sufficient to maintain the injectable-grade water limit.

DMF is incompatible with strong oxidizing agents, acid chlorides, acyl halides, and certain halogenated compounds; such mixtures may generate heat and degradation products. Storage in contact with copper or brass should be avoided because trace metal leaching and discoloration may occur. Gaskets and seals should be polytetrafluoroethylene or high-density polyethylene; polyvinyl chloride, polycarbonate, and ethylene-propylene-diene-monomer rubber may swell or soften in contact with DMF.

For oral solutions, DMF is typically introduced at the pre-mix stage with propylene glycol or glycerol to reduce local solvent concentration before aqueous dilution. The solution is mixed in a stainless-steel tank with a bottom-entry agitator at 50–150 rpm; high-shear dispersion is not required because DMF is fully miscible and free of particulate matter. Filtration through a 10 µm polypropylene cartridge before storage removes incidental contamination. pH is adjusted after addition of DMF because DMF may shift apparent pH readings in low-buffer systems; finished oral solutions are tested for dimethylamine and formic acid at release and at the retest interval.

In granule and premix lines, the measured residual DMF by headspace GC should be included in batch records as a release parameter only when DMF is used downstream of the final crystallization or granulation step. If DMF is used as a cleaning solvent for vessels and transfer lines, carry-over must be demonstrated below the ICH Q3C(R8) Option 2 limit of 880 ppm in the next product batch or in rinse samples. Equipment cleaning validation using swab sampling and headspace GC is preferred over visual inspection because DMF is colorless and low-viscosity residues may not be visibly detectable. The absence of a final drying step for liquid oral solutions makes pre-blend solvent selection and rinse control the principal corrective action when residual DMF exceeds specification.